论文部分内容阅读
化疗的进展虽已大大地改善了滋养细胞肿瘤的预后,但绒癌的缓解率仍不令人满意。某些病人对联合化疗耐药。当前,化疗药物的选择及方案制定只根据大量病例临床资料的统计学评价而非具体肿瘤对化疗的反应,急需建立一种能预测化疗疗效的方法。本研究应用肾被膜下测定(Subrenal Capsule Assay,SRCA)判断绒癌对不同化疗的反应。正常具有免疫能力的ddY杂交鼠做为移植受体。3个妊娠绒癌细胞株(J.C.K.、H.S.及H.M.)做为实验肿瘤。提供肿瘤的三个病人中J.C.K.及H.M.虽经手术及强烈化疗死于肿瘤播散,而H.S.经联合化疗达完全缓解。
Although the progress of chemotherapy has greatly improved the prognosis of trophoblastic tumors, the remission rate of choriocarcinoma remains unsatisfactory. Some patients are resistant to combination chemotherapy. Currently, the choice of chemotherapeutic agents and their formulation are based solely on the statistical evaluation of clinical data from a large number of cases rather than on the response of specific tumors to chemotherapy, and there is an urgent need to establish a method that can predict the efficacy of chemotherapy. In this study, Subrenal Capsule Assay (SRCA) was used to determine the response of choriocarcinoma to different chemotherapies. The normal immune ddY hybrid mice as transplant recipients. Three pregnant choriocarcinoma cell lines (J.C.K., H.S. and H.M.) served as experimental tumors. Among the three patients who provided the tumor, J.C.K. and H.M. died of tumor dissemination by surgery and intensive chemotherapy, whereas H.S. was completely relieved by combination chemotherapy.